---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276906"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:38:41.064248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports Phase 1b KOMET-001 data for ziftomenib in R/R AML; 600 mg shows 25% CR/CRh

## Summary
- Phase 1b at 600 mg (N=12): 25% CR/CRh rate, 33% composite CR (75% MRD-), 42% ORR.
- Phase 1a (N=30): 2 DLTs (pneumonitis at 400 mg, differentiation syndrome at 1000 mg); manageable safety.
- Differentiation syndrome occurred in 7 Phase 1b patients; severity declined after DS Guidance implementation.
- Oral presentation at ASH on Dec 10, 2022, will include preliminary data from 18 additional Phase 1b extension patients.
- Ziftomenib is an oral menin-KMT2A inhibitor targeting NPM1m and KMT2Ar relapsed/refractory AML.

## SEC filing metadata
- accession: 0001193125-22-276906
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312522276906/0001193125-22-276906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312522276906/d366823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276906
- JSON: https://secwatch.observer/filing/0001193125-22-276906.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.